Oral gene delivery:: Design of polymeric carrier systems shielding toward intestinal enzymatic attack

被引:22
作者
Martien, Ronny [1 ]
Loretz, Brigitta [1 ]
Schnuerch, A. B. [1 ]
机构
[1] Univ Innsbruck, Dept Pharmaceut Technol, Inst Pharm, A-6020 Innsbruck, Austria
关键词
enzyme inhibitor; nanoparticles; enzymatic degradation; chitosan; aurintricarboxylic acid (ATA); Caco-2 cell line; therapeutic genes;
D O I
10.1002/bip.20521
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The gastrointestinal tract poses a variety of morphological and physiological barriers to the expression of target genes. The aim of this study was to evaluate the stability of cationic polymer/pDNA nanoparticles toward salts and enzymes of the intestinal fluid. Within this study, a chitosan-enzyme inhibitor conjugate has been generated and characterized. Based on this conjugate, nanoparticles with pDNA were generated to enhance transfection rate in oral gene delivery. The enzyme inhibitor aurintricarboxylic acid (ATA) was covalently bound to chitosan to improve the enzymatic stability of nanoparticles formed with this polymer and pDNA. Chitosan-ATA/pDNA nanoparticles showed a size of 98.5 +/- 26 nm and a zeta potential of -13.26 +/- 0.24 mV (n = 3-4). Stability studies with salt solution, lysozyme, DNase, and freshly collected porcine intestinal fluid showed that chitosan-ATA/pDNA nanoparticles are significantly (p < 0.05) more stable than unmodified chitosan/pDNA nanoparticles. Apart from improved stability, chitosan-ATA/pDNA nanoparticles showed a 2.6-fold higher transfection rate than chitosan/pDNA nanoparticles in the Caco-2 cell line, thus creating a promising carrier for orally administered therapeutic genes. (c) 2006 Wiley Periodicals, Inc.
引用
收藏
页码:327 / 336
页数:10
相关论文
共 38 条
[1]   Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor [J].
Aktas, Y ;
Andrieux, K ;
Alonso, MJ ;
Calvo, P ;
Gürsoy, RN ;
Couvreur, P ;
Çapan, Y .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 298 (02) :378-383
[2]   Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection [J].
Barry, ME ;
Pinto-González, D ;
Orson, FM ;
McKenzie, GJ ;
Petry, GR ;
Barry, MA .
HUMAN GENE THERAPY, 1999, 10 (15) :2461-2480
[3]  
BASEL CGA, 2005, WISS TABELLEN GEIGY
[4]   The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins [J].
Bernkop-Schnurch, A .
JOURNAL OF CONTROLLED RELEASE, 1998, 52 (1-2) :1-16
[6]   DNA condensation [J].
Bloomfield, VA .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 1996, 6 (03) :334-341
[7]   Preparation of coated nanoparticles for a new mucosal vaccine delivery system [J].
Borges, O ;
Borchard, G ;
Verhoef, JC ;
de Sousa, A ;
Junginger, HE .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 299 (1-2) :155-166
[8]   PRACTICAL ANALYSIS OF COMPLEX COACERVATE SYSTEMS [J].
BURGESS, DJ .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 1990, 140 (01) :227-238
[9]   Effect of surface charge on the stability of oil/water emulsions during steam sterilization [J].
Chansiri, G ;
Lyons, RT ;
Patel, MV ;
Hem, SL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (04) :454-458
[10]   Inhibition of cytokine-induced JAK-STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid [J].
Chen, CW ;
Chao, Y ;
Chang, YH ;
Hsu, MJ ;
Lin, WW .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (07) :1011-1020